RegulatoryCompany release

Amylyx Phase 3 avexitide trial succeeds in post-bariatric hypoglycemia; NDA planned by year-end

🇺🇸 Amylyx Pharmaceuticals, Inc. (AMLX) · Thu 05 Nov 2026

Amylyx reported positive Phase 3 LUCIDITY results alongside Q3 figures, saying it will file with the FDA by the end of 2026 for avexitide, which has Breakthrough Therapy Designation.

Amylyx Pharmaceuticals reported third-quarter 2026 results on 5 November, highlighting positive Phase 3 LUCIDITY data for avexitide in post-bariatric hypoglycemia (PBH). The company said the treatment cut Level 2 and 3 hypoglycemic events by 55% compared with placebo.

Amylyx plans to submit a New Drug Application (NDA) to the US Food and Drug Administration by the end of 2026. Avexitide already holds Breakthrough Therapy Designation, an FDA status intended to speed the development and review of drugs for serious conditions where early evidence suggests a substantial improvement over existing options.

The company intends to present the LUCIDITY data at ObesityWeek on 15 November.

On the financial side, Amylyx reported a public offering with net proceeds of about $544.6 million and cash of $768.1 million at the end of the quarter. The summary available does not include further detail on trial design, safety findings or the timing of an FDA decision.

What it means for your team

  • Regulatory teams should watch for the NDA submission, promised by end-2026, and for any FDA acceptance and review-timeline announcement that follows.
  • Full LUCIDITY results at ObesityWeek on 15 November should show the safety data and how Level 2 and 3 events were defined, which matter for labelling and risk-management planning.
  • Market-access teams tracking PBH, a condition that arises after bariatric surgery, should note that a first approved therapy could shape future payer and evidence discussions.

Company's press release (SEC filing): Amylyx Pharmaceuticals, Inc. ↗

Article written by VigiEye from the official source (Amylyx Pharmaceuticals, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Regulatory All →